{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T12:07:34Z","timestamp":1792670854069,"version":"4.5.0"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T00:00:00Z","timestamp":1752537600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Infect Dis Ther"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s40121-025-01190-7","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T15:25:24Z","timestamp":1752593124000},"page":"1843-1865","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW-TT) Administered with Routine Pediatric Vaccines: A European Randomized Controlled Trial"],"prefix":"10.1007","volume":"14","clinical-trial-number":[{"clinical-trial-number":"nct03547271","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Federico","family":"Martinon-Torres","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miia M.","family":"Virta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Koski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ignacio Salamanca","family":"de la Cueva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henryk T.","family":"Szymanski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Bosis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca C.","family":"Dr\u0103g\u0103nescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven-Arne","family":"Silfverdal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Betzana","family":"Zambrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mandeep S.","family":"Dhingra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siham","family":"B\u2019Chir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Syrkina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Lyabis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo A.","family":"Vasquez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Rehm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"The MET58 Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,15]]},"reference":[{"issue":"12","key":"1190_CR1","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/S1473-3099(10)70251-6","volume":"10","author":"H Christensen","year":"2010","unstructured":"Christensen H, May M, Bowen L, Hickman M, Trotter CL. Meningococcal carriage by age: a systematic review and meta-analysis. Lancet Infect Dis. 2010;10(12):853\u201361. https:\/\/doi.org\/10.1016\/S1473-3099(10)70251-6.","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"1190_CR2","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1016\/j.vaccine.2024.02.064","volume":"42","author":"A Huber","year":"2024","unstructured":"Huber A, Kov\u00e1cs E, Horv\u00e1th A, et al. Prevalence, serogroup distribution and risk factors of Neisseria meningitidis carriage in high school and university students in Hungary. Vaccine. 2024;42(9):2271\u20137. https:\/\/doi.org\/10.1016\/j.vaccine.2024.02.064.","journal-title":"Vaccine"},{"key":"1190_CR3","unstructured":"European Centre for Disease Prevention and Control. Invasive meningococcal disease: annual epidemiological report for 2022. https:\/\/www.ecdc.europa.eu\/en\/publications-data\/monitoring\/all-annual-epidemiological-reports. Accessed 11 Dec 2024."},{"issue":"4","key":"1190_CR4","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.jinf.2020.05.079","volume":"81","author":"SR Parikh","year":"2020","unstructured":"Parikh SR, Campbell H, Bettinger JA, et al. The everchanging epidemiology of meningococcal disease worldwide and the potential for prevention through vaccination. J Infect. 2020;81(4):483\u201398. https:\/\/doi.org\/10.1016\/j.jinf.2020.05.079.","journal-title":"J Infect"},{"issue":"1","key":"1190_CR5","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1186\/s12879-024-09547-y","volume":"24","author":"S Taha","year":"2024","unstructured":"Taha S, Deghmane AE, Taha MK. Recent increase in atypical presentations of invasive meningococcal disease in France. BMC Infect Dis. 2024;24(1):640. https:\/\/doi.org\/10.1186\/s12879-024-09547-y.","journal-title":"BMC Infect Dis"},{"issue":"3","key":"1190_CR6","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1007\/s10719-022-10050-2","volume":"39","author":"R Kensinger","year":"2022","unstructured":"Kensinger R, Arunachalam AB. Preclinical development of the quadrivalent meningococcal (ACYW) tetanus toxoid conjugate vaccine, MenQuadfi(R). Glycoconj J. 2022;39(3):381\u201392. https:\/\/doi.org\/10.1007\/s10719-022-10050-2.","journal-title":"Glycoconj J"},{"issue":"9","key":"1190_CR7","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1080\/14760584.2021.1964962","volume":"20","author":"F Martin\u00f3n-Torres","year":"2021","unstructured":"Martin\u00f3n-Torres F, Bertrand-Gerentes I, Oster P. A novel vaccine to prevent meningococcal disease beyond the first year of life: an early review of MenACYW-TT. Expert Rev Vaccines. 2021;20(9):1123\u201346. https:\/\/doi.org\/10.1080\/14760584.2021.1964962.","journal-title":"Expert Rev Vaccines"},{"key":"1190_CR8","unstructured":"European Medicines Agency. MenQuadfi: EPAR\u2014risk management plan. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/menquadfi. Accessed 19 June 2025."},{"issue":"10","key":"1190_CR9","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1016\/j.vaccine.2022.01.050","volume":"40","author":"MJ Cornish","year":"2022","unstructured":"Cornish MJ, Hedrick JA, Gabrielsen AA, et al. Safety and immunogenicity of an investigational quadrivalent meningococcal tetanus toxoid conjugate vaccine (MenACYW-TT) co-administered with routine pediatric vaccines in infants and toddlers: a phase II study. Vaccine. 2022;40(10):1421\u201338. https:\/\/doi.org\/10.1016\/j.vaccine.2022.01.050.","journal-title":"Vaccine"},{"issue":"Supplement 1","key":"1190_CR10","doi-asserted-by":"publisher","first-page":"ofae631.079","DOI":"10.1093\/ofid\/ofae631.079","volume":"12","author":"J CampbellBetzana Zambrano","year":"2025","unstructured":"CampbellBetzana Zambrano J, Dhingra MS, Gupta S, et al. 221. Immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) when co-administered with routine pediatric vaccines in healthy infants and toddlers in the US and Puerto Rico. Open Forum Infect Dis. 2025;12(Supplement 1):ofae631.079. https:\/\/doi.org\/10.1093\/ofid\/ofae631.079.","journal-title":"Open Forum Infect Dis"},{"key":"1190_CR11","unstructured":"Immunogenicity and safety study of an investigational quadrivalent meningococcal conjugate vaccine administered concomitantly with routine pediatric vaccines in healthy infants and toddlers. https:\/\/clinicaltrials.gov\/study\/NCT03691610."},{"key":"1190_CR12","unstructured":"Cheryl Duffy, Olga Lyabis, Mandeep Singh Dhingra, et al. A phase III, partially modified double-blind, randomized, parallel-group, active-controlled, multi-center study to compare the immunogenicity and describe the safety of MenACYW conjugate vaccine and MENVEO\u00ae when administered concomitantly with routine pediatric vaccines to healthy infants and toddlers in the United States. https:\/\/clinicaltrials.gov\/study\/NCT03537508."},{"issue":"Suppl 1","key":"1190_CR13","doi-asserted-by":"publisher","first-page":"ofae631.829","DOI":"10.1093\/ofid\/ofae631.829","volume":"12","author":"A Moskow","year":"2025","unstructured":"Moskow A, Zambrano B, Dhingra MS, et al. P-632. Safety of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) administered concomitantly with routine pediatric vaccines in healthy infants and toddlers. Open Forum Infect Dis. 2025;12(Suppl 1):ofae631.829. https:\/\/doi.org\/10.1093\/ofid\/ofae631.829. (eCollection 2025 Feb).","journal-title":"Open Forum Infect Dis"},{"key":"1190_CR14","unstructured":"Inc. P. Pfizer receives EU approval for Nimenrix vaccine in infants. https:\/\/www.pharmaceuticalprocessingworld.com\/pfizer-receives-eu-approval-for-nimenrix-vaccine-in-infants\/. Accessed 2 June 2025."},{"key":"1190_CR15","unstructured":"European Centre for Disease Prevention and Control. Vaccine schedules in all countries in the EU\/EAA. https:\/\/vaccine-schedule.ecdc.europa.eu\/. Accessed 5 Mar 2025."},{"issue":"11","key":"1190_CR16","doi-asserted-by":"publisher","first-page":"1173","DOI":"10.1097\/INF.0b013e318268dfe4","volume":"31","author":"LM Pina","year":"2012","unstructured":"Pina LM, Bassily E, Machmer A, Hou V, Reinhardt A. Safety and immunogenicity of a quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine in infants and toddlers: three multicenter phase III studies. Pediatr Infect Dis J. 2012;31(11):1173\u201383. https:\/\/doi.org\/10.1097\/INF.0b013e318268dfe4.","journal-title":"Pediatr Infect Dis J"},{"issue":"7","key":"1190_CR17","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1128\/CVI.00131-10","volume":"17","author":"SA Plotkin","year":"2010","unstructured":"Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010;17(7):1055\u201365. https:\/\/doi.org\/10.1128\/CVI.00131-10.","journal-title":"Clin Vaccine Immunol"},{"issue":"6","key":"1190_CR18","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1080\/14760584.2021.1940144","volume":"21","author":"J Findlow","year":"2022","unstructured":"Findlow J, Lucidarme J, Taha MK, Burman C, Balmer P. Correlates of protection for meningococcal surface protein vaccines: lessons from the past. Expert Rev Vaccines. 2022;21(6):739\u201351. https:\/\/doi.org\/10.1080\/14760584.2021.1940144.","journal-title":"Expert Rev Vaccines"},{"issue":"9","key":"1190_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6909a1","volume":"69","author":"SA Mbaeyi","year":"2020","unstructured":"Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal vaccination: recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep. 2020;69(9):1\u201341. https:\/\/doi.org\/10.15585\/mmwr.rr6909a1.","journal-title":"MMWR Recomm Rep"},{"issue":"17\u201318","key":"1190_CR20","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1016\/j.vaccine.2005.01.051","volume":"23","author":"R Borrow","year":"2005","unstructured":"Borrow R, Balmer P, Miller E. Meningococcal surrogates of protection\u2013serum bactericidal antibody activity. Vaccine. 2005;23(17\u201318):2222\u20137. https:\/\/doi.org\/10.1016\/j.vaccine.2005.01.051.","journal-title":"Vaccine"},{"issue":"47","key":"1190_CR21","first-page":"521","volume":"86","author":"World Health Organization","year":"2011","unstructured":"World Health Organization. Meningococcal vaccines: WHO position paper, November 2011. Wkly Epidemiol Rec. 2011;86(47):521\u201339.","journal-title":"Wkly Epidemiol Rec"},{"issue":"4","key":"1190_CR22","doi-asserted-by":"publisher","first-page":"e98","DOI":"10.1097\/INF.0000000000001484","volume":"36","author":"JM Merino Arribas","year":"2017","unstructured":"Merino Arribas JM, Carmona Martinez A, Horn M, et al. Safety and immunogenicity of the quadrivalent meningococcal serogroups A, C, W and Y tetanus toxoid conjugate vaccine coadministered with routine childhood vaccines in European infants: an open, randomized trial. Pediatr Infect Dis J. 2017;36(4):e98\u2013107. https:\/\/doi.org\/10.1097\/INF.0000000000001484.","journal-title":"Pediatr Infect Dis J"},{"key":"1190_CR23","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1017\/S0950268821000261","volume":"149","author":"D van der Vliet","year":"2021","unstructured":"van der Vliet D, Vesikari T, Sandner B, et al. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) vs. a licensed quadrivalent meningococcal tetanus toxoid-conjugate vaccine in meningococcal vaccine-naive and meningococcal C conjugate vaccine-primed toddlers: a phase III randomised study. Epidemiol Infect. 2021;149:e50. https:\/\/doi.org\/10.1017\/S0950268821000261.","journal-title":"Epidemiol Infect"},{"issue":"6","key":"1190_CR24","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1080\/21645515.2020.1733869","volume":"16","author":"T Vesikari","year":"2020","unstructured":"Vesikari T, Borrow R, Forsten A, Findlow H, Dhingra MS, Jordanov E. Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in healthy toddlers: a phase II randomized study. Hum Vaccines Immunother. 2020;16(6):1306\u201312. https:\/\/doi.org\/10.1080\/21645515.2020.1733869.","journal-title":"Hum Vaccines Immunother"},{"issue":"33","key":"1190_CR25","doi-asserted-by":"publisher","first-page":"5194","DOI":"10.1016\/j.vaccine.2020.06.013","volume":"38","author":"MS Dhingra","year":"2020","unstructured":"Dhingra MS, Peterson J, Hedrick J, Pan J, Neveu D, Jordanov E. Immunogenicity, safety and inter-lot consistency of a meningococcal conjugate vaccine (MenACYW-TT) in adolescents and adults: a phase III randomized study. Vaccine. 2020;38(33):5194\u2013201. https:\/\/doi.org\/10.1016\/j.vaccine.2020.06.013.","journal-title":"Vaccine"},{"issue":"28","key":"1190_CR26","doi-asserted-by":"publisher","first-page":"4102","DOI":"10.1016\/j.vaccine.2018.05.046","volume":"36","author":"G Dbaibo","year":"2018","unstructured":"Dbaibo G, Tinoco Favila JC, Traskine M, Jastorff A, Van der Wielen M. Immunogenicity and safety of MenACWY-TT, a meningococcal conjugate vaccine, co-administered with routine childhood vaccine in healthy infants: a phase III, randomized study. Vaccine. 2018;36(28):4102\u201311. https:\/\/doi.org\/10.1016\/j.vaccine.2018.05.046.","journal-title":"Vaccine"},{"issue":"7","key":"1190_CR27","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1097\/INF.0000000000002061","volume":"37","author":"JM Merino Arribas","year":"2018","unstructured":"Merino Arribas JM, Carmona Martinez A, Horn M, et al. Immunogenicity and reactogenicity of DTPa-HBV-IPV\/Hib and PHiD-CV when coadministered with MenACWY-TT in infants: results of an open, randomized trial. Pediatr Infect Dis J. 2018;37(7):704\u201314. https:\/\/doi.org\/10.1097\/INF.0000000000002061.","journal-title":"Pediatr Infect Dis J"},{"issue":"10","key":"1190_CR28","doi-asserted-by":"publisher","first-page":"2491","DOI":"10.1080\/21645515.2019.1593082","volume":"15","author":"J Findlow","year":"2019","unstructured":"Findlow J, Balmer P, Borrow R. A review of complement sources used in serum bactericidal assays for evaluating immune responses to meningococcal ACWY conjugate vaccines. Hum Vaccines Immunother. 2019;15(10):2491\u2013500. https:\/\/doi.org\/10.1080\/21645515.2019.1593082.","journal-title":"Hum Vaccines Immunother"},{"issue":"1","key":"1190_CR29","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.vaccine.2011.10.068","volume":"30","author":"CJ Gill","year":"2011","unstructured":"Gill CJ, Ram S, Welsch JA, Detora L, Anemona A. Correlation between serum bactericidal activity against Neisseria meningitidis serogroups A, C, W-135 and Y measured using human versus rabbit serum as the complement source. Vaccine. 2011;30(1):29\u201334. https:\/\/doi.org\/10.1016\/j.vaccine.2011.10.068.","journal-title":"Vaccine"}],"container-title":["Infectious Diseases and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01190-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40121-025-01190-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40121-025-01190-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,11]],"date-time":"2025-08-11T11:56:43Z","timestamp":1754913403000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40121-025-01190-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,15]]},"references-count":29,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1190"],"URL":"https:\/\/doi.org\/10.1007\/s40121-025-01190-7","relation":{},"ISSN":["2193-8229","2193-6382"],"issn-type":[{"value":"2193-8229","type":"print"},{"value":"2193-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,15]]},"assertion":[{"value":"13 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Betzana Zambrano, Mandeep Singh Dhingra, Siham B\u2019Chir, Olga Syrkina, Olga Lyabis, Christine Rehm, and Gustavo Vasquez are employees of Sanofi and may hold shares and\/or stock options in the company. Federico Martinon-Torres has acted as principal investigator in this trial and also in other randomized controlled trials of Ablynx, Abbot, Seqirus, Sanofi Pasteur MSD, Sanofi Pasteur, Cubist, Wyeth, Merck, Pfizer, Roche, Regeneron, Jansen, Medimmune, Moderna, Novavax, Novartis, and GSK, with honoraria paid to his institution. He also reports consulting or advisory relationship with AstraZeneca, GSK Vaccines SRL, BioNet, Biofabri, Pfizer Inc, Sanofi Pasteur Inc, Seqirus Janssen Pharmaceuticals Inc, and MSD. Susanna Koski acted as a principal investigator for the study reported in this manuscript, which was sponsored by Sanofi. She is an employee of Finnish Vaccine Research (FVR), which conducts clinical vaccine studies for many major vaccine manufacturers, including Sanofi. Henryk T Szymanski reports personal fees and trial fees paid to his institution from MSD, Seqirus, Pfizer, Janssen, and Sanofi Pasteur. Miia Virta, Ignacio Salamanca de la Cueva and Samantha Bosis have no conflicts of interest to declare. Anca Cristina Dr\u0103g\u0103nescu acted as a principal investigator for the study reported in this manuscript, which was sponsored by Sanofi. Sven-Arne Silfverdal acted as a principal investigator for the study reported in this manuscript, which was funded by Sanofi, and also for other trials sponsored by GSK, Jansen, Medimmune, MSD, and Pfizer. He has been a member of advisory boards for Astra, GSK, MSD, Pfizer, and Sanofi Pasteur, with honoraria to his institution or personal.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was conducted in compliance with the International Conference on Harmonisation guidelines for Good Clinical Practice and the principles of the Declaration of Helsinki. Informed consent was obtained from participants\u2019 parents (or legal guardian) before any study procedures were performed. The protocol and any amendments were approved by applicable independent ethics committees or institutional review boards at each participating site and the appropriate regulatory agencies in each country (Supplementary methods).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}